Zacks: Analysts expect Minerva Surgical, Inc. (NASDAQ: UTRS) to report earnings of -$0.31 per share
Wall Street brokers expect Minerva Surgical, Inc. (NASDAQ: UTRS – Get Rating) to report ($0.31) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts provided earnings estimates for Minerva Surgical, with the highest EPS estimate of $0.30 and the lowest estimate of $0.32. The company is expected to release its next quarterly results after the market closes on Monday, January 1.
According to Zacks, analysts expect Minerva Surgical to report annual earnings of $1.03 per share for the current fiscal year, with EPS estimates ranging from $1.09 to $0.96. For the next fiscal year, analysts expect the company to post earnings of ($0.88) per share, with EPS estimates ranging from ($0.90) to ($0.86). Zacks Investment Research’s EPS calculations are an average average based on a survey of research companies that track Minerva Surgical.
The UTRS has been the subject of several reports by research analysts. Piper Sandler lowered its price target on Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating on the stock in a Wednesday, March 9 report. Zacks Investment Research upgraded Minerva Surgical from a “buy” rating to a “hold” rating in a Saturday, March 12 report. One equity research analyst gave the stock a hold rating and four gave the company’s stock a buy rating. Based on MarketBeat data, Minerva Surgical currently has a consensus rating of “Buy” and an average target price of $11.70.
UTRS stock opened at $2.42 on Thursday. The company has a debt ratio of 0.89, a quick ratio of 2.60 and a current ratio of 3.29. Minerva Surgical has a 12 month minimum of $2.24 and a 12 month maximum of $10.37. The company has a 50-day moving average price of $4.56.
Several institutional investors have recently changed their holdings to UTRS. Virtu Financial LLC acquired a new stock position in Minerva Surgical during Q4 for a value of approximately $54,000. Renaissance Technologies LLC acquired a new stock position in Minerva Surgical during Q4 worth approximately $78,000. BlackRock Inc. acquired a new position in shares of Minerva Surgical during Q4 worth approximately $88,000. Millennium Management LLC acquired a new stock position in Minerva Surgical during Q4 worth approximately $134,000. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Minerva Surgical during Q4 worth approximately $386,000. Institutional investors and hedge funds hold 42.40% of the company’s shares.
About Minerva Surgical (Get an assessment)
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures and markets minimally invasive solutions to meet the uterine health needs of women in the United States. The Company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system that combines bladeless tissue resection and coagulation, continuous visualization and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a portable surgical instrument for hysteroscopic ablation and diagnosis of endometrial polyps.
Get a Free Copy of Zacks Research Report on Minerva Surgical (UTRS)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Minerva Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Minerva Surgical and related companies with MarketBeat.com’s free daily email newsletter.